Regeneron Research Poster

News

Regeneron To Buy 23andMe For $256M

Regeneron to buy 23andMe out of bankruptcy for $256 million

Regeneron, a biotech company, will acquire 23andMe for $256 million and vowed to comply with the genetic testing company's privacy policies.

· 2d · on MSN

Regeneron to buy bankrupt 23andMe, vows ethical use of customer DNA data

· 2d · on MSN

Regeneron Pharmaceuticals to buy 23andMe for $256M

22h

Regeneron's 23andMe Steal - Smart Genetics Play That Won't Cure Near-Term Growth Pains

Regeneron acquired 23andMe for $256M, gaining 15M DNA profiles to enhance R&D. Find out why REGN stock is a Buy.

MedCity News2d

23andMe Bankruptcy Auction Win Adds Big Piece to Regeneron’s Gene-Based Drug R&D Efforts

Regeneron Pharmaceuticals’ $256 million offer was chosen the winner of 23andMe’s bankruptcy auction. Drug research never ...

Yahoo Finance2d

Regeneron buys bankrupt 23andMe for $256m

the auction will see Regeneron acquire the majority of 23andMe’s assets. This includes the company’s Personal Genome Service (PGS) and Total Health and Research Services business lines ...

Regeneron to buy 23andMe out of bankruptcy for $256 mn

Regeneron Pharmaceuticals said Monday it will buy genetic testing company 23andMe out of bankruptcy for $256 million, a deal ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results